Takeda (TAK)

Takeda (TAK) stock research: performance, analysts' price targets, earnings, revenue and margins, technicals and insider trades.

Japan Drug Designation Keeps Takeda Pipeline in Focus

Takeda rose 2.6% today as attention stays on Japan’s priority designation for its experimental stomach cancer drug. Shares are at the top of their 52-week range, while traders look ahead to the company’s next report in January.

Published 2026-11-20 15:01:38 UTC.